AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis

RINVOQ received European Union approval to treat active polyarticular juvenile idiopathic arthritis in patients aged two years and older who have had an inadequate response or intolerance to one or more DMARDs. The approval, supported by open-label Phase 1 data, expands the drug's eligible patient population and provides a positive regulatory catalyst for its manufacturer.